2013
Treatment of early diffuse systemic sclerosis skin disease.
Frech TM, Shanmugam VK, Shah AA, Assassi S, Gordon JK, Hant FN, Hinchcliff ME, Steen V, Khanna D, Kayser C, Domsic RT. Treatment of early diffuse systemic sclerosis skin disease. Clinical And Experimental Rheumatology 2013, 31: 166-71. PMID: 23910619, PMCID: PMC3889109.Peer-Reviewed Original ResearchConceptsSSc skin diseaseSystemic sclerosisSkin diseasesEarly diffuse cutaneous systemic sclerosisDiffuse cutaneous systemic sclerosisEarly diffuse SScEarly systemic sclerosisCutaneous systemic sclerosisDiffuse systemic sclerosisIncident cohort studyIntravenous immunoglobulinProspective registryCohort studyInter-institutional variabilityClinical courseHigh morbidityDiffuse SScEffective treatmentNovel biomarkersDisease pathogenesisSclerosisDiseaseTreatmentRigorous studiesMycophenolate
2007
Obliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapy
Hinchcliff M, Varga J. Obliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapy. Expert Review Of Clinical Immunology 2007, 3: 11-15. PMID: 20476946, DOI: 10.1586/1744666x.3.1.11.Peer-Reviewed Original ResearchSystemic sclerosisObliterative vasculopathyOpen-label clinical trialEfficacy of statinsChronic cardiovascular diseasePrecursor cellsSerious clinical manifestationsEndothelial precursor cellsChronic vasculopathyVascular obliterationClinical manifestationsVascular damageVascular precursor cellsClinical trialsTherapeutic roleCardiovascular diseaseEffective treatmentImpaired productionVasculopathySclerosisNovel targetStatinsDefective vasculogenesisAtorvastatinEndothelial precursors